Navigating Non-Muscle Invasive Bladder Cancer: A Population Health and Payer Perspective
Mark D. Tyson II, M.D., MPH, discusses how recent updates to clinical guidelines now cautiously embrace bladder-sparing gene therapies like nadofaragene for patients with BCG-unresponsive non-muscle invasive bladder cancer, exploring the evolving treatment landscape, operational challenges, and real-world implementation strategies that are shifting the field toward more personalized, less invasive approaches while maintaining oncologic efficacy.
An expert discusses how recent updates to AUA, EAU and NCCN guidelines have cautiously shifted toward more bladder-sparing approaches for BCG-unresponsive patients, incorporating new FDA-approved therapies as conditional recommendations for those unwilling or unable to undergo radical cystectomy.
Watch
EP. 2: Applying Evidence Standards to Guide Gene Therapy Use in BCG-Unresponsive NMIBC
July 17th 2025An expert discusses how high-cost gene therapies require evidence standards including Phase 3 trial data showing complete response rates and durability, real-world evidence and health economic analyses to guide clinical use and coverage determinations before payers scrutinize their carte blanche approval.
Watch
